Alleviation of Cholestatic Liver Injury and Intestinal Permeability by Lubiprostone Treatment in Bile Duct Ligated Rats: Role of Intestinal FXR and Tight Junction Proteins Claudin-1, Claudin-2, and Occludin

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 2023 Mar 10

PMID 36897372

Authors

Fereydoon Safari

Mohammadreza Sharifi

Ardeshir Talebi

Nasrin Mehranfard

Maedeh Ghasemi

Affiliations

Soon will be listed here.

Abstract

Gut barrier disintegrity and endotoxin translocation to the liver and systemic circulation are serious clinical complications associated with the stoppage of intestinal bile flow. There is no precise pharmacological option to prevent increased intestinal permeability after bile duct ligation (BDL). Lubiprostone, a chloride channel-2 agonist, has been shown to accelerate restoration of epithelial barrier dysfunction caused by injury, but the exact mechanisms underlying the beneficial effects of lubiprostone on intestine barrier integrity remain unknown. Here, we assessed the beneficial effect of lubiprostone on cholestasis caused by BDL and relevant mechanisms. Male rats were subjected to BDL for 21 days. Seven days after BDL induction, lubiprostone was administered twice daily (10 µg/kg of body weight). Intestinal permeability was assessed through measurements of serum lipopolysaccharide (LPS) concentration. Real-time PCR was conducted to assess expression of intestinal claudin-1 occludin and FXR genes, which are important in preserving the intestinal epithelial barrier integrity, as well as claudin-2 being involved in a leaky gut barrier. Histopathological alterations were also monitored for liver injury. Lubiprostone significantly decreased BDL-induced systemic LPS elevation in rats. BDL induced a significant reduction in FXR, occludin, and claudin-1 genes expression, while increased claudin-2 expression in rat colon. Treatment with lubiprostone significantly restored expression of these genes to the control values. BDL also increased the level of hepatic enzymes ALT, ALP, AST, and total bilirubin, while lubiprostone could preserve the hepatic enzymes and total bilirubin in the treated BDL rats. Lubiprostone also caused a significant reduction in BDL-induced liver fibrosis and intestinal damage in rats. Our results suggest that lubiprostone favorably prevents BDL-induced alterations in intestinal epithelial barrier integrity possibly via modulating intestinal FXRs and tight junction gene expression.

Citing Articles

Therapeutic effects of composite probiotics derived from fermented camel milk on metabolic dysregulation and intestinal barrier integrity in type 2 diabetes rats.

Manaer T, Sailike J, Sun X, Yeerjiang B, Nabi X Front Pharmacol. 2025; 15():1520158.

PMID: 39840100 PMC: 11747018. DOI: 10.3389/fphar.2024.1520158.

References

Adachi Y, Moore L, Bradford B, Gao W, Thurman R . Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology. 1995; 108(1):218-24. DOI: 10.1016/0016-5085(95)90027-6. View

Albillos A, De Gottardi A, Rescigno M . The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2019; 72(3):558-577. DOI: 10.1016/j.jhep.2019.10.003. View

Arakawa K, Ishigami T, Nakai-Sugiyama M, Chen L, Doi H, Kino T . Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice. PLoS One. 2019; 14(6):e0218096. PMC: 6576757. DOI: 10.1371/journal.pone.0218096. View

Belinchon-Romero I, Bellot P, Romero-Perez D, Herraiz-Romero I, Marco F, Frances R . Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients. Sci Rep. 2021; 11(1):8593. PMC: 8060289. DOI: 10.1038/s41598-021-88043-8. View

Chazouilleres O . Novel Aspects in the Management of Cholestatic Liver Diseases. Dig Dis. 2016; 34(4):340-6. DOI: 10.1159/000444544. View

Enomoto N, Ikejima K, Yamashina S, Hirose M, Shimizu H, Kitamura T . Kupffer cell sensitization by alcohol involves increased permeability to gut-derived endotoxin. Alcohol Clin Exp Res. 2001; 25(6 Suppl):51S-4S. DOI: 10.1097/00000374-200106001-00012. View

Enomoto M, Kaji K, Nishimura N, Fujimoto Y, Murata K, Takeda S . Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis. Dig Liver Dis. 2022; 54(10):1392-1402. DOI: 10.1016/j.dld.2022.04.012. View

Forman B, Goode E, Chen J, Oro A, Bradley D, Perlmann T . Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 1995; 81(5):687-93. DOI: 10.1016/0092-8674(95)90530-8. View

Gadaleta R, van Erpecum K, Oldenburg B, Willemsen E, Renooij W, Murzilli S . Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011; 60(4):463-72. DOI: 10.1136/gut.2010.212159. View

10.

Gijbels E, Pieters A, De Muynck K, Vinken M, Devisscher L . Rodent models of cholestatic liver disease: A practical guide for translational research. Liver Int. 2021; 41(4):656-682. PMC: 8048655. DOI: 10.1111/liv.14800. View

11.

Hegyi P, Maleth J, Walters J, Hofmann A, Keely S . Guts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease. Physiol Rev. 2018; 98(4):1983-2023. DOI: 10.1152/physrev.00054.2017. View

12.

Inagaki T, Moschetta A, Lee Y, Peng L, Zhao G, Downes M . Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006; 103(10):3920-5. PMC: 1450165. DOI: 10.1073/pnas.0509592103. View

13.

Isaacs-Ten A, Echeandia M, Moreno-Gonzalez M, Brion A, Goldson A, Philo M . Intestinal Microbiome-Macrophage Crosstalk Contributes to Cholestatic Liver Disease by Promoting Intestinal Permeability in Mice. Hepatology. 2020; 72(6):2090-2108. PMC: 7839474. DOI: 10.1002/hep.31228. View

14.

Jin Y, Pridgen T, Blikslager A . Pharmaceutical Activation or Genetic Absence of ClC-2 Alters Tight Junctions During Experimental Colitis. Inflamm Bowel Dis. 2015; 21(12):2747-57. DOI: 10.1097/MIB.0000000000000550. View

15.

Jonker J, Liddle C, Downes M . FXR and PXR: potential therapeutic targets in cholestasis. J Steroid Biochem Mol Biol. 2011; 130(3-5):147-58. PMC: 4750880. DOI: 10.1016/j.jsbmb.2011.06.012. View

16.

Kato T, Honda Y, Kurita Y, Iwasaki A, Sato T, Kessoku T . Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers. PLoS One. 2017; 12(4):e0175626. PMC: 5391961. DOI: 10.1371/journal.pone.0175626. View

17.

Lacy B, Levy L . Lubiprostone: a chloride channel activator. J Clin Gastroenterol. 2007; 41(4):345-51. DOI: 10.1097/01.mcg.0000225665.68920.df. View

18.

Li W, Yang H, Zhao Q, Wang X, Zhang J, Zhao X . Polyphenol-Rich Loquat Fruit Extract Prevents Fructose-Induced Nonalcoholic Fatty Liver Disease by Modulating Glycometabolism, Lipometabolism, Oxidative Stress, Inflammation, Intestinal Barrier, and Gut Microbiota in Mice. J Agric Food Chem. 2019; 67(27):7726-7737. DOI: 10.1021/acs.jafc.9b02523. View

19.

Nighot P, Blikslager A . Chloride channel ClC-2 modulates tight junction barrier function via intracellular trafficking of occludin. Am J Physiol Cell Physiol. 2011; 302(1):C178-87. DOI: 10.1152/ajpcell.00072.2011. View

21.

Nighot P, Leung L, Ma T . Chloride channel ClC- 2 enhances intestinal epithelial tight junction barrier function via regulation of caveolin-1 and caveolar trafficking of occludin. Exp Cell Res. 2017; 352(1):113-122. PMC: 5328798. DOI: 10.1016/j.yexcr.2017.01.024. View